Featured Research

from universities, journals, and other organizations

High potency statins linked to better outcome following heart attack

Date:
February 20, 2014
Source:
University of Dundee
Summary:
Treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins, a study concludes after analyzing the data of thousands of patients who suffered heart attacks. The study also found a combination of statins and the drug ezetimibe showed no improved survival rate, although researchers caution this finding needs further testing.

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment with high-potency statins offers a significantly improved chance of survival compared to those taking normal statins.

Related Articles


The study, led by the University of Dundee, also found a combination of statins and the drug ezetimibe showed no improved survival rate, although researchers caution this finding needs further testing.

'There is presently a lot of interest in ezetimibe as a potential treatment for heart patients,' said Professor Chim Lang, from the Division of Cardiovascular and Diabetes Medicine at the University of Dundee Medical School.

'Ezetimibe has been shown to be very effective at lowering cholesterol but we do not know its effect on survival. The key question really is whether it is better than statins, especially high potency statins such as rosuvastatin or atorvastatin.

'What our study has showed, looking at the data from thousands of patients in the UK, is that patients who switched from normal statin treatment to high potency statins lived longer.

'Those who had ezetimibe added did not appear to have a better outcome. So for the moment the data supports the use of high potency statins, one of which, atorvastatin, is now off patent and is cheap and effective.'

Results of the study have been published online in the journal Heart.

Data for the study was drawn from the UK's Clinical Practice Research Datalink. Researchers looked at the data for patients who had survived 30 days after their first heart attack, who had not received prior statin or ezetimibe therapy, and who were started on a statin within that period of their attack.

The data of 9597 patients was used. 6990 of those were treated with simvastatin, 1883 had switched to a more potent statin, and 724 were given an ezetimibe/statin combination.

Data for the group was analyzed for an average 3.2 years from the start point of their first heart attack. During that time there were 1134 deaths.

The results showed that patients who switched to a high-potency statin had a 28% lower risk of death compared to those who received simvastatin. There was no observed benefit of adding ezetimibe.


Story Source:

The above story is based on materials provided by University of Dundee. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Pauriah, D. H. J. Elder, S. Ogston, A. Y. S. Noman, A. Majeed, J. C. Wyatt, A.-M. Choy, T. M. MacDonald, A. D. Struthers, C. C. Lang. High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart, 2014; DOI: 10.1136/heartjnl-2013-304678

Cite This Page:

University of Dundee. "High potency statins linked to better outcome following heart attack." ScienceDaily. ScienceDaily, 20 February 2014. <www.sciencedaily.com/releases/2014/02/140220102923.htm>.
University of Dundee. (2014, February 20). High potency statins linked to better outcome following heart attack. ScienceDaily. Retrieved February 27, 2015 from www.sciencedaily.com/releases/2014/02/140220102923.htm
University of Dundee. "High potency statins linked to better outcome following heart attack." ScienceDaily. www.sciencedaily.com/releases/2014/02/140220102923.htm (accessed February 27, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, February 27, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New FDA-Approved Diabetes Medicine Might Save Drugmaker

New FDA-Approved Diabetes Medicine Might Save Drugmaker

Newsy (Feb. 26, 2015) The U.S. Food and Drug Administration approved new diabetes drug Toujeo on Wednesday, a move that might save French drugmaker Sanofi&apos;s profits. Video provided by Newsy
Powered by NewsLook.com
The Best Foods to Battle Stress

The Best Foods to Battle Stress

Buzz60 (Feb. 26, 2015) If you&apos;re dealing with anxiety, there are a few foods that can help. Krystin Goodwin (@krystingoodwin) has the best foods to tame stress. Video provided by Buzz60
Powered by NewsLook.com
The 5 Best Tips to Look Younger Now

The 5 Best Tips to Look Younger Now

Buzz60 (Feb. 26, 2015) Life happens, and we all get older, but forget the pricey anti-aging products and plastic surgery. You can tweak your habits to turn back the hands of time. Krystin Goodwin (@krystingoodwin) has a few simple tips to help you look and feel younger. Video provided by Buzz60
Powered by NewsLook.com
Sleeping Too Much Or Too Little Might Increase Stroke Risk

Sleeping Too Much Or Too Little Might Increase Stroke Risk

Newsy (Feb. 26, 2015) People who sleep more than eight hours per night are 45 percent more likely to have a stroke, according to a University of Cambridge study. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins